Loading organizations...
§ Private Profile · York, York, United Kingdom
Developer of Optimer® aptamer binders, synthetic antibody alternatives for life sciences, diagnostics, and therapeutics.
Based in York, United Kingdom, Aptamer Group was founded in 2008 by Arron Tolley and David Bunka to develop synthetic nucleic acid alternatives to traditional antibodies, known as Optimer binders. The organization provides custom aptamer discovery and development services to major global pharmaceutical and biotechnology partners, including AstraZeneca, PinotBio, and Novavax, for use in diagnostics, targeted drug delivery, and therapeutic treatments. The publicly traded life sciences company operates a B2B service and licensing model, generating its revenue through upfront research fees, clinical development milestones, and ongoing commercial royalties. Listed on the London Stock Exchange's AIM market, the firm raised £10,800,000 during its December 2021 initial public offering at an £80,700,000 valuation. Currently operating with a specialized team of 28 employees, the business later completed a corporate refinancing round of £3,600,000 in August 2023 to stabilize its operations.
Aptamer Group has raised $6.8M across 2 funding rounds.
Aptamer Group has raised $6.8M in total across 2 funding rounds.
Aptamer Group has raised $6.8M across 2 funding rounds. Most recently, it raised $4.6M Other Equity in July 2023.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 31, 2023 | $4.6M Venture Round | — | — | Announced |
| Jun 29, 2018 | $2.2M Series A | Meneldor | — | Announced |
Aptamer Group has raised $6.8M in total across 2 funding rounds.
Aptamer Group's investors include Meneldor.